ICIs are monoclonal antibodies that can target and block immune checkpoints, such as PD-1 and CTLA-4 on T cells or PD-L1 on tumor cells, thus inhibiting tumor immune escape and enhancing the antitumor function of T cells (5). This evidence concerns the gene CTLA4 and neoplasm.